Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 11Neuroblastoma 7Lymphoma 7Neoplasms, Plasma Cell 5Immunoglobulin Light-chain Amyloidosis 5Hodgkin Disease 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Biphenotypic, Acute 3Leukemia 3Ganglioneuroblastoma 3Waldenstrom Macroglobulinemia 2Sarcoma, Ewing 2Preleukemia 2Precancerous Conditions 2Neoplasms by Histologic Type 2Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphatic Diseases 2Leukemia, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphoid 2Leukemia, B-Cell 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2

Interventions

Amifostine 4Cisplatin 3Radiotherapy 2Paclitaxel 2Filgrastim 2Carboplatin 2Peripheral Blood Stem Cell Transplantation 1Octreotide 1Melphalan 1Furosemide 1Etoposide 1Erythropoietin 1Epoetin Alfa 1Duloxetine Hydrochloride 1Brachytherapy 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Drug-Related Side Effects and Adverse Reactions × Melphalan × Clear all
NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Eastern Cooperative Oncology Group

Phase 1 Terminated
8 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡